Research Professor

Myoung-Hee Kang, Ph.D.

Research professor
  • E-MAIL

  • Ph.D. in cancer biology, Department of Biomedical Science, Korea University

Academic Background

  • 1Diabetic foot ulcers
  • 2Reverse aging
  • 3Alopecia areata (Hair loss)
  • 4Translational research, Epigenetics, RNA biology, Cancer genomics

Education & Research Experience

  • 2022-present

    Research professor, Department of Plastic and Reconstructive surgery SMG-SNU Boramae Medical Center

  • 2020-2021

    Research professor, Ulsan college of Medicine, Biomedical Research center, Institute for Asan Life Sciences, Asan Medical Center

  • 2017-2018

    Postdoc Fellow, Department of Biomedical Engineering, School of Life Sciences, Ulsan National Institute of Science and Technology(UNIST)

  • 2014-2017

    Research professor, National Research Fellow program for Ulsan college of Medicine, Lab of Cancer Genomics, Biomedical Research center, Institute for Asan Life Sciences, Asan Medical Center

  • 2012-2014

    Research Fellow, Brain Korea 21 program for Biomedical Science, National Research Fellow program for Korea University College of Medicine

  • 2007-2012

    Ph.D. course, major in Cancer biology, the biomedical science, Korea University


  • 2022-2027

    세종과학펠로우십 / 연구책임자

  • 2019-2022

    창의도전연구자지원사업 / 연구책임자

  • 2017-2018

    박사후국외연수사업 / 연구책임자

  • 2013-2016

    리서치펠로우사업 / 연구책임자

Honors and Awards

  • 2012.02

    Best Thesis Award, Korea University Graduate School

  • 2009.10

    Excellent Poster Award, Korea Society for Molecular and Cellular Biology (KSMCB)

  • 2008.06

    Glaxo Smith Kline (GSK) Scientific Award, The Annual Meeting of Korean cancer Association

  • 2007-2012

    Winning a Scholarship for participant Researcher of BK21 project from the Korea Research Foundation


  • 2017

    Pharmaceutical composition for preventing or treating gastric cancer comprising verteporfin as active ingredient (10-17740999) Korea

  • 2019

    Biomarker for predicting resistance or sensitivity to anticancer agent comprising ALDH3A1 (10-1941668) Korea

Publications (SCI Publication List)

  • 01

    Choi YJ, Lee HJ, Kim DS, Kim DH, Kang MH, Cho YH, Choi CM, Yoo JK, Lee KO, Choi EK, Lee JC, Rho JK. Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer. European J Pharmacology. 2021 Sep 15;907:174298. (IF: 5.195)

  • 02

    Kim DH, Park HJ, Choi YJ, Kang MH, Kim TK, Pack CG, Choi CM, Lee JC, Rho JK. Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2. Cell Death & Disease. 2021 Jul 28;12(8):747. (IF : 9.705)

  • 03

    Kang MH, Eyun SI, Park YY. Estrogen-related receptor-gamma influences Helicobacter pylori infection by regulating TFF1 in gastric cancer. Biochemical and Biophysical Research Communications. 2021 Jul 23;563:15-22, Epub 2021 May 28.(IF : 3.322)

  • 04

    Ji WJ, Choi YJ, Kang MH, Sung KJ, Kim DH, Jung SY, Choi CM, Lee JC, Rho JK. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines. Cells. 2020 Dec 3;9(12):2596 (IF : 7.666)

  • 05

    Jung YD, Park SK, Kang D, Hwang S, Kang MH, Hong SW, Moon JH, Shin JK, Jin DH, Dalsan Youd, Lee JY, Park YY, Hwang JJ, Kim CS, Suh NY.
    Epigenetic regulation of miR-29a/miR-30c/DNMT3A axis controls SOD2 and mitochondrial oxidative stress in human mesenchymal stem cells.
    Redox Biology. 2020 Oct;37:101716 (IF:10.787)

  • 06

    Cho JM, Lee HJ, Chung JH, Kim WY, Kang MH, Ha KS, Woo SU, Lee JB. Papillary Thyroid Cancer Tumor Spheres Cultured by Passaging Without Sorting Exhibit Cancer Stemness. Anticancer Research. 2020 Jul;40(7):3801-3809 (IF: 2.435)

  • 07

    Kim SJ, Ju JS, Kang MH, Eun JW, Kim YH, Raninga GV, Khanna KK, Balázs Győrffy, Pack CG, Han HD, Lee HJ, Gong GY, Shin Y, Mills GB, Eyun SI, Park YY. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020 Jul 2;10(18):7974-7992. (IF: 11.6)

  • 08

    Kim GH, Lee G, Kang MH, Kim MJ, Jin YS, Beck SJ, Cheon JH, Sung JY, Joo JM. Luminescent Silicon Nanoparticles for Distinctive Tracking of Cellular Targeting and Trafficking. Faraday Discussions. 2020 Jul;40(7):3801-3809 (IF: 4.394)

  • 09

    Park YS, Yoo JH, Kang MH*, Kwon WS, Joo JM. Photoluminescent and Biodegradable Porous Silicon Nanoparticles for Biomedical Imaging.
    Journal of Materials Chemistry B. 2019 Nov 7. 7 (41), 6271-6292 (IF:7.571)

  • 10

    Park AR, Park HJ, Yoon JS, Kang DY, Kang MH, Park YY, Suh NY, Yu JH. Priming with Toll-like receptor 3 agonist or interferon-gamma enhances the therapeutic effects of human mesenchymal stem cells in a murine model of atopic dermatitis. Stem Cell Research & Therapy.
    2019 Feb 22;10(1):66. (IF: 8.098)

  • 11

    Kang SH, Kim BR, Kang MH, Kim DY, Lee DH, Oh SC, Min BW, Um JW. Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial–mesenchymal transition in human colon cancer cells. PloS One. 2018 Oct 11, 13,10; e02305449. (IF :3.752)

  • 12

    Kang MH, Choi HJ, Lee JH, M Oshima, Cheong JH, Kim SH, Choi HS, Kweon MN, Pack CG, Lee JS, Mills,GB, Myung SJ, Park YY. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. Nature communications. 2018 May 15;9(1):1920.(IF:17.694)

  • 13

    Lee SW, Kwak HS, Kang MH, Park YY, Jeong GS. Fibroblast-associated tumour microenvironment induces vascular structure-networked tumouroid.
    Scientific Reports. 2018 Feb 5;8(1):2365. doi: 10.1038/s41598-018-20886-0. (IF:4.996)

  • 14

    Kang MH, Jeong GS, Duane T Smoot, Hassan Ashktora, Hwang CM, Park YY. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1. Oncotarget. 2017 Oct 19;8(58):98887-98897 (IF: 5.168)

  • 15

    Kang MH, Jeong KJ, Kim WY, Lee HJ, Gong G, Suh N, Győrffy B, Kim S, Jeong SY, Mills GB, Park YY. Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer. Oncogene. 2017 Mar 23;36(12):1745-1752. doi: 10.1038/onc.2016.327. (IF:8.756)

  • 16

    Kim BR*, Kang MH*, Kim JL, Na YJ, Park SH, Lee SI, Kang SH, Joung SY, Lee SY, Lee DH, Min BW, Oh SC. RUNX3 inhibits the metastasis and angiogenesis of colorectal cancer. Oncology Reports 2016 Nov;36(5):2601-2608 -– Co-first author (IF: 4.136)

  • 17

    Kim DS, Na YJ, Kang MH, Yoon SY, Choi CW. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. Korean J Intern Med. 2016 Mar,31 : 357-366 (IF: 3.165)

  • 18

    Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, Pradeep S, Hwang JE, Jang HJ, Lee HS, Rupaimoole R, Lopez-Berestein G, Jeong W, Park IS, Park YN, Sood AK, Mills GB, Lee JS. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. HEPATOLOGY. 2016 Jan;63 (1):159-72. (2016) (IF: 17.298)

  • 19

    Kim BR, Oh SC, Lee DH, Kim JL, Lee SY, Kang MH, Lee SI, Kang S, Joung SY, Min BW. BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation. Tumor Biology. 2015 Jun 30 ;36(12):9475-86 (2015) (IF: 3.65)

  • 20

    Hwang JW*, Kang MH*, Yoo YA, Quan YH, Kim HK, Oh SC, Choi YH. The effects of sonic hedgehog signaling pathway components on non-small-cell lung cancer progression and clinical outcome. WORLD JOURNAL OF SURGICAL ONCOLOGY. 2014 Aug 21;12:268 – Co-first author (IF: 3.253)

  • 21

    Yoo YA *, Kang MH*, Lee HJ, Kim BH, Park JK, Kim HJ, Kim JS, and Oh SC. Sonic Hedgehog Pathway Promotes Metastasis and Lymphangiogenesis via Activation of Akt, EMT, and MMP-9 Pathway in Gastric Cancer. Cancer Research. 2011 Nov 15;71(22):7061-70. – Co-first author (IF: 13.312)

  • 22

    Kang MH, Oh SC, Lee HJ, Kim BH, Kang HN, Kim JL, Kim JS, and Yoo YA. Metastatic function of BMP-2 in gastric cancer cells: role of PI3K/AKT-MAPK-NF-κB pathway and MMP-9 expression. Experimental Cell Res. 2011 Jul 15;317(12):1746-62. (IF: 4.145)

  • 23

    Kim JL, Kang HN, Kang MH, Yoo YA, Kim JS, Choi CW. The Oral Iron Chelator Deferasirox Induces Apoptosis in Myeloid Leukemia Cells by Targeting Caspase. ACTA HAEMATOLOGICA 126:241–2452011(2011)2011 sep 27 (IF:3.068)

  • 24

    Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Experimental Cell Res. 2010 Jan 1;316(1):24-37 (IF: 4.145)

  • 25

    Kang MH, Kang HN, Kim JL, Kim JS, Oh SC, Yoo YA. Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion.
    Oncology Reports. 2009 Sep;22(3):525-34 (IF:4.136)

  • 26

    Park Y, Kang MH, Oh SC, Seo JH, Kim BS, Kim JS. Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression. Medical Oncology. 2010 Dec;27(4):1192-9. (IF:3.738)

  • 27

    Yoo YA, Kang MH, Kim BS, Kim JS, Seo JH. Sustained co-cultivation with human placenta-derived MSCs enhances ALK5/Smad3 signaling in human breast epithelial cells, leading to EMT and differentiation. Differentiation. 2009 Jun;77(5):450-61. (IF: 3.533)

  • 28

    Yoo YA, Kang MH, Kim JS, Oh SC. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-β-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis. 2008 Mar;29(3):480-90. (IF: 4.741)